- Report
- February 2026
- 250 Pages
Global
From €4216EUR$4,490USD£3,517GBP
- Report
- February 2026
- 250 Pages
Global
From €4216EUR$4,490USD£3,517GBP
- Report
- February 2026
- 250 Pages
Global
From €4216EUR$4,490USD£3,517GBP
- Report
- May 2026
- 185 Pages
Global
From €4225EUR$4,500USD£3,525GBP
- Report
- May 2026
- 185 Pages
Global
From €4225EUR$4,500USD£3,525GBP
- Report
- May 2026
- 177 Pages
Global
From €4225EUR$4,500USD£3,525GBP
- Report
- January 2026
- 180 Pages
Global
From €4225EUR$4,500USD£3,525GBP
- Report
- January 2026
- 181 Pages
Global
From €4225EUR$4,500USD£3,525GBP
- Drug Pipelines
- September 2026
- 150 Pages
Global
From €3521EUR$3,750USD£2,937GBP
- Report
- September 2026
- 130 Pages
Global
From €4460EUR$4,750USD£3,721GBP
- Report
- August 2026
- 110 Pages
Global
From €4460EUR$4,750USD£3,721GBP
- Report
- July 2026
- 120 Pages
Global
From €4460EUR$4,750USD£3,721GBP
- Report
- July 2026
- 70 Pages
Global
From €4460EUR$4,750USD£3,721GBP
- Report
- May 2026
- 140 Pages
Global
From €4460EUR$4,750USD£3,721GBP
- Report
- May 2026
- 140 Pages
Global
From €4460EUR$4,750USD£3,721GBP
- Report
- September 2026
- 200 Pages
Global
From €7502EUR$7,990USD£6,259GBP
- Report
- September 2026
- 120 Pages
Global
From €7502EUR$7,990USD£6,259GBP
- Report
- September 2026
- 450 Pages
Global
From €4695EUR$5,000USD£3,917GBP
- Drug Pipelines
- September 2026
- 150 Pages
Global
From €3521EUR$3,750USD£2,937GBP
- Clinical Trials
- April 2026
- 180 Pages
Global
From €1878EUR$2,000USD£1,567GBP

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more